Skip to main content
OpenTrials
Completed

NCT Number: NCT04510376

Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method

Single-center, monadic, one day study utilizing the skin prick method to assess the allergy potential of Omeza Collagen Matrix in Human Subjects

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

PCR Corp

St. Petersburg, Florida, 33702, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers aged 18 years of age and older as demonstrated by selfreported medical history, concurrent medication, and a brief dermal skin assessment of the test sites;
  • Fully informed of the risks of entering the study and willing to provide written informed consent and HIPAA authorization to disclose protected health information;
  • Subject has normal healthy skin on the either volar forearm.

Exclusion criteria

Subjects must be excluded if any of the following conditions exist:

  • Self-reported pregnant or nursing at the screening visit;
  • Clinically significant skin disease which may contraindicate participation, including psoriasis, eczema, atopic dermatitis, and active cancer;
  • History of drug abuse or current drug user;
  • Treatment with antihistamine or steroid (any route) administered within the last 7 days;
  • History of anaphylaxis to matrix ingredients (e.g. fish, palm oil, hemp oil, beeswax);
  • Persistent severe/ unstable asthma;
  • Subjects on beta blockers and/or ACE inhibitors;
  • Medical condition which in the opinion of the Investigator would compromise the safety of the subject or confound study results (Subjects with the following conditions: chronic renal failure, CVA, cancer, spinal cord injury, diabetic neuropathy, recent anaphylaxis, limbs affected by lymphoedema, paralysis, or neurogenic abnormalities;
  • Diabetic (type 1 or 2);
  • Subjects taking the following: Antidepressants such as doxepin, other tricyclics, Phenothiazines, and tetracyclics within the last two weeks;
  • Subjects taking OTC cold and flu remedies, "sinus" analgesics, antitussives, antiemetics, sedatives, relaxants, migraine prophylactics (cyproheptadine, pizotifen);
  • Prolonged use of topical corticosteroids;
  • Use of topical moisturizers on the volar forearms;
  • Dermographism "writing on the skin" - common localized hive reaction, characterized by the abrupt onset of welts and hives where the skin is exposed to pressure, scratching, itching, or stroking;
  • Investigator deems the subject an unsuitable candidate for this study.

Treatment and study plan

Test Article

Device

Omeza Collagen Matrix

Positive Control

Other

1.0 mg/mL Histamine Base

Negative Control

Other

Aqueous Negative Control

Primary outcomes

  1. Allergic Reaction

    Time frame: 20 minutes

    Response of at least 3-mm diameter (with equivalent erythema) more than negative control is required as proof of presence of cutaneous allergen specific IgE

Secondary outcomes

  1. Allergic Reaction

    Time frame: 60 minutes

    Latent reaction to skin prick (safety assessment)

Sponsors and collaborators

Lead sponsor

Omeza, LLC

Industry

Registry information

Official study title

A Safety Study to Assess the Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Aug 12, 2020
Registry last updated
Aug 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.